The Experts below are selected from a list of 393 Experts worldwide ranked by ideXlab platform
David Kastenberg - One of the best experts on this subject based on the ideXlab platform.
-
the effect on colon visualization during colonoscopy of the addition of Simethicone to polyethylene glycol electrolyte solution a randomized single blind study
Clinical and translational gastroenterology, 2012Co-Authors: Rebecca Matro, Constantine Daskalakis, Leo Katz, Keegan Tupchong, Victoria Gordon, David KastenbergAbstract:The Effect on Colon Visualization During Colonoscopy of the Addition of Simethicone to Polyethylene Glycol-Electrolyte Solution: A Randomized Single-Blind Study
Massimo Martinelli - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of a standardized extract of matricariae chamomilla l melissa officinalis l and tyndallized lactobacillus acidophilus ha122 in infantile colic an open randomized controlled trial
Neurogastroenterology and Motility, 2017Co-Authors: Massimo Martinelli, Dario Ummarino, Elisa Sciorio, F P Giugliano, C Tortora, Dario Bruzzese, D De Giovanni, Irene Rutigliano, S Valenti, Claudio RomanoAbstract:Background Infant colic (IC) is a prevalent physiological event of infants, which can disrupt the child's home environment. We aimed to investigate the effectiveness of a mixture of Matricariae chamomilla L., Melissa officinalis L. and tyndallized Lactobacillus acidophilus (HA122) compared with Lactobacillus reuteri DSM 17938 and with Simethicone for the treatment of IC. Methods A multicenter randomized comparative study was conducted in infants with colic, according to Rome III criteria, who were randomly assigned to receive M. chamomilla L., M. officinalis L. and tyndallized L. acidophilus (HA122) (Colimil® Plus®; Milte Italia Spa, Milan, Italy) (Group A), L. reuteri DSM 17938 (Group B) and Simethicone (Group C). Treatment was given to subjects for 28 days. Key Results One-hundred and seventy-six patients completed the study. Mean daily crying time at day 28 was significantly lower in group A (−44, 95% CI: −58 to −30, P<.001) and group B (−35, 95% CI: −49 to −20, P<.001) when compared to group C. No significant difference was observed between Group A and Group B (mean difference: −9 minutes, 95% CI −23 to +5, P=.205). At day 28, 39 of 57 (68.4%) of infants in Group C responded to the treatment compared with 57 out of 60 patients (95%) of Group A and 51 out of 59 (86.4%) of Group B (P<.001). Conclusions This study suggests that administration of M. chamomilla L., M. officinalis L. and tyndallized L. acidophilus (HA122) and L. reuteri DSM 17938 are significantly more effective than Simethicone in IC. Clinical Trial Registration: ClinicalTrials.gov: NCT02708238.
-
effect of magnesium alginate plus Simethicone on gastroesophageal reflux in infants
Journal of Pediatric Gastroenterology and Nutrition, 2015Co-Authors: Dario Ummarino, Erasmo Miele, Massimo Martinelli, Elena Scarpato, Felice Crocetto, Elisa Sciorio, Annamaria StaianoAbstract:ABSTRACTObjectives:Gastroesophageal reflux (GER) is a frequently occurring condition in infants capable of causing distressing symptoms. The aim of our study is to evaluate the efficacy of Mg alginate plus Simethicone (Gastrotuss Baby, DMG Italia SRL, Pomezia, Italy), compared with rice-starch–thick
-
Effect of Magnesium Alginate Plus Simethicone on Gastroesophageal Reflux in Infants
'Ovid Technologies (Wolters Kluwer Health)', 2014Co-Authors: Dario Ummarino, Erasmo Miele, Massimo Martinelli, Elena Scarpato, Felice Crocetto, Elisa Sciorio, Annamaria StaianoAbstract:OBJECTIVES: Gastroesophageal reflux (GER) is a frequently occurring condition in infants capable of causing distressing symptoms. The aim of our study is to evaluate the efficacy of Mg alginate plus Simethicone (Gastrotuss Baby, DMG Italia SRL, Pomezia, Italy), compared with rice-starch-thickened formula or with reassurance alone, in the treatment of GER in infants. METHODS: The present randomized controlled trial was conducted in full-term infants affected by symptoms suggestive of GER, evaluated through a validated questionnaire (Infant Gastroesophageal Reflux Questionnaire Revised). The patients were randomized into 3 groups according to treatment (group A: Mg alginate plus Simethicone; group B: thickened formula; group C: reassurance with lifestyle changes). Evaluation of symptom scores was performed after 1 month (T1) and 2 months (T2). RESULTS: A total of 64 (85.3%) of 75 enrolled infants (median age 5 months; range 1-10) concluded the study. After 1 month of treatment (T1), infants treated with Mg alginate plus Simethicone showed a statistically significant improvement in symptoms compared with the thickened formula and reassurance (P
Claudio Romano - One of the best experts on this subject based on the ideXlab platform.
-
efficacy of a standardized extract of matricariae chamomilla l melissa officinalis l and tyndallized lactobacillus acidophilus ha122 in infantile colic an open randomized controlled trial
Neurogastroenterology and Motility, 2017Co-Authors: Massimo Martinelli, Dario Ummarino, Elisa Sciorio, F P Giugliano, C Tortora, Dario Bruzzese, D De Giovanni, Irene Rutigliano, S Valenti, Claudio RomanoAbstract:Background Infant colic (IC) is a prevalent physiological event of infants, which can disrupt the child's home environment. We aimed to investigate the effectiveness of a mixture of Matricariae chamomilla L., Melissa officinalis L. and tyndallized Lactobacillus acidophilus (HA122) compared with Lactobacillus reuteri DSM 17938 and with Simethicone for the treatment of IC. Methods A multicenter randomized comparative study was conducted in infants with colic, according to Rome III criteria, who were randomly assigned to receive M. chamomilla L., M. officinalis L. and tyndallized L. acidophilus (HA122) (Colimil® Plus®; Milte Italia Spa, Milan, Italy) (Group A), L. reuteri DSM 17938 (Group B) and Simethicone (Group C). Treatment was given to subjects for 28 days. Key Results One-hundred and seventy-six patients completed the study. Mean daily crying time at day 28 was significantly lower in group A (−44, 95% CI: −58 to −30, P<.001) and group B (−35, 95% CI: −49 to −20, P<.001) when compared to group C. No significant difference was observed between Group A and Group B (mean difference: −9 minutes, 95% CI −23 to +5, P=.205). At day 28, 39 of 57 (68.4%) of infants in Group C responded to the treatment compared with 57 out of 60 patients (95%) of Group A and 51 out of 59 (86.4%) of Group B (P<.001). Conclusions This study suggests that administration of M. chamomilla L., M. officinalis L. and tyndallized L. acidophilus (HA122) and L. reuteri DSM 17938 are significantly more effective than Simethicone in IC. Clinical Trial Registration: ClinicalTrials.gov: NCT02708238.
W E Fleig - One of the best experts on this subject based on the ideXlab platform.
-
Simethicone for small bowel preparation for capsule endoscopy a systematic single blinded controlled study
Gastrointestinal Endoscopy, 2004Co-Authors: J Albert, Christamaria Gobel, Joachim Leske, E Lotterer, H H Nietsch, W E FleigAbstract:Abstract Background Capsule endoscopy is a new imaging method for visualization of the entire small bowel. However, no standardized protocol for bowel preparation for capsule endoscopy has been evaluated. Methods Capsule endoscopy was performed in 36 consecutive patients, all of whom fasted for 12 hours before ingestion of the capsule. Before capsule endoscopy, 18 patients received 80 mg Simethicone and 18 had no supplemental medication for bowel preparation. Two observers, both experienced endoscopists, independently reviewed the examinations in a single-blinded and randomly assigned fashion. Mucosal visibility and intraluminal gas bubbles were assessed and graded by both observers. Results Bowel preparation with Simethicone resulted in significantly better visibility because of fewer intraluminal bubbles ( p Conclusions Simethicone may be added to the routine preparation for capsule endoscopy to improve the visibility of small bowel mucosa.
Gerald Holtmann - One of the best experts on this subject based on the ideXlab platform.
-
influence of Simethicone added to the rinse water during colonoscopies on polyp detection rates results of an unintended cohort study
Digestion, 2018Co-Authors: Marguerite J Kutyla, Sam Oconnor, Saravana Ruban Gurusamy, Montri Gururatsakul, Kelly Gould, Amanda Whaley, Bradley J Kendall, Luke F Hourigan, Gerald HoltmannAbstract:Background and Aims: Simethicone is a common antifoaming agent that is added to endoscopic rinse solutions, but data regarding its effect on polyp detection rates is lacking. In this study, we report the effect of discontinuation of this practice on polyp detection rates. Methods: Procedure data of 4,254 consecutive colonoscopies were used. Patients underwent standard bowel preparation with polyethyleneglycol (Glycoprep®). Colonoscopies were performed utilising Olympus EVIS EXERA III, CV-190 equipment, while quality data (withdraw times, polyp detection rates, quality of bowel preparation) was assessed utilising an endoscopy reporting system (Provation®). Following an educational event that highlighted that Simethicone may form deposits in the channels of endoscopes, the practice to add Simethicone (InfacolR, Nice Pak) to the auxiliary channel water pump was abandoned, but endoscopists were not notified about this change. After 5 days and performing 75 colonoscopies, the change of practice was identified and addition of Simethicone recommenced. Results: The discontinuation of Simethicone use reduced the polyp detection rate from 55% (95% CI 53–56) to 45% (95% CI 34–56, 1-sided, p = 0.028); the polyp detection rate returned to the pre-intervention levels of 55% (95% CI 52–58) upon resumption of normal practice. Conclusion: The addition of Simethicone to the auxiliary water pump during colonoscopy results in a 10% increase in polyp detection rates.
-
a randomized placebo controlled trial of Simethicone and cisapride for the treatment of patients with functional dyspepsia
Alimentary Pharmacology & Therapeutics, 2002Co-Authors: Gerald Holtmann, J M Gschossmann, P Mayr, Nicholas J TalleyAbstract:SUMMARY Aim : To compare the efficacy of Simethicone with placebo and the prokinetic cisapride in patients with functional dyspepsia. Methods : One hundred and eighty-five patients with functional dyspepsia were randomized and treated in a double-dummy technique with Simethicone (105 mg t.d.s.), cisapride (10 mg t.d.s.) or placebo (t.d.s.). The primary outcome measure was the O'Brien global measure of the patients' rating of 10 upper gastrointestinal symptoms (graded as absent=0, moderate=1, severe=2 or very severe=3). Outcome measures were assessed at baseline and after 2, 4 and 8 weeks of treatment (intention-to-treat). Results : At 2, 4 and 8 weeks, treatment with Simethicone and cisapride yielded significantly (all P values < 0.0001) better improvement of symptoms compared to placebo. Simethicone was significantly better than cisapride after 2 weeks (P=0.0007), but the differences were not statistically significant after 4 and 8 weeks. Patients treated with Simethicone judged the efficacy of their treatment as very good in 46% of cases, compared to 15% and 16% receiving cisapride and placebo, respectively. Conclusions : Simethicone and cisapride were significantly better than placebo for symptom control in patients with functional dyspepsia after 2, 4 and 8 weeks of treatment. Simethicone was also superior to the prokinetic cisapride in the first 2 weeks of treatment.
-
randomised double blind comparison of Simethicone with cisapride in functional dyspepsia
Alimentary Pharmacology & Therapeutics, 1999Co-Authors: Gerald Holtmann, J M Gschossmann, P Mayr, M Karaus, T Fischer, B Becker, Guido GerkenAbstract:Aim : To compare the efficacy of Simethicone with cisapride in patients with functional (non-ulcer) dyspepsia. Methods : After standardized diagnostic work-up and at least 6-days wash-out of medication, 177 patients with functional dyspepsia were enrolled; 173 of them (age 19–71 years) were randomized and treated using a double-dummy technique with Simethicone (84 mg t.d.s.) or cisapride (10 mg t.d.s.). At baseline and after 2 and 4 weeks, the intensity of the symptoms was scored from 0 (absent) to 3 (severe) using a standardized symptom questionnaire. Efficacy of the treatment was judged by the patients as ‘very good’, ‘good’, ‘moderate’ or ‘no effect’. Results : A total of 166 patients completed the trial. After 2 and 4 weeks, 34% and 46% (respectively), of the patients treated with Simethicone judged the improvement in symptoms to be excellent compared to 13% and 22% (respectively) of patients treated with cisapride (P < 0.01). After 2 weeks the difference in the improvement in the global symptom score was significantly better (Δ30.7%, P < 0.001) for Simethicone than for cisapride, while this difference failed statistical significance after 4 weeks (Δ10.2%, P=0.11). Conclusions : In patients with functional dyspepsia, Simethicone relieves symptoms during the first 2 weeks of treatment significantly better than cisapride.
